Travopine B 1.5 Eye Drop contains Timolol 5mg/ml + Brimonidine 1.5mg/ml, a dual-action anti-glaucoma ophthalmic formulation used for effective reduction of elevated intraocular pressure in patients with glaucoma and ocular hypertension. Its well-balanced combination ensures reliable and sustained pressure control.
The eye drop works by reducing aqueous humor production through Timolol and decreasing aqueous formation while enhancing outflow via Brimonidine, providing comprehensive intraocular pressure management and optic nerve protection.
From a franchise perspective, Travopine B 1.5 Eye Drop is a high-demand combination therapy, commonly prescribed in eye hospitals, ophthalmology clinics, and glaucoma care centers, ensuring steady prescriptions and repeat business.
Adding Travopine B 1.5 Eye Drop to your portfolio strengthens the ophthalmic anti-glaucoma combination segment, offering long-term market stability, strong prescriber confidence, and enhanced portfolio value for PCD pharma franchise partners.